Study protocol of KeyPemls‐004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non‐small cell lung cancer and progressive disease (PD) after immunotherapy (PD‐1/PD‐L1 inhibitor) alone or in combination with platinum‐doublet chemotherapy

INTRODUCTION: Immune checkpoint inhibitor (ICI)‐based treatment regimens have become the standard of care for first‐line treatment of metastatic epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) wild‐type non‐small cell lung cancer (NSCLC). Nevertheless, most patients inevitab...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jia, Chen, Minjiang, Gao, Xiaoxing, Liu, Xiaoyan, Zhao, Jing, Pan, Ruili, Zhong, Wei, Xu, Yan, Wang, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008678/
https://www.ncbi.nlm.nih.gov/pubmed/36725772
http://dx.doi.org/10.1111/1759-7714.14806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008678/
https://www.ncbi.nlm.nih.gov/pubmed/36725772
http://dx.doi.org/10.1111/1759-7714.14806

Ejemplares similares